Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781803 | 0.86 | HTR2A (0.48) | RAB9AHTR2AALDH1A1MAPTGAA | |
| SCHEMBL8975833 | 0.84 | IDO1 (0.51) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| SCHEMBL1555636 | 0.83 | ALDH1A1 (0.59) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| SCHEMBL29171050 | 0.83 | HTR2A (0.59) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| SCHEMBL7729899 | 0.82 | ALDH1A1 (0.58) | RAB9AIDO1ALDH1A1MAPTAKR1C3 | |
| SCHEMBL5235557 | 0.82 | IDO1 (0.56) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| SCHEMBL9782567 | 0.82 | IDO1 (0.56) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| SCHEMBL9820376 | 0.82 | IDO1 (0.56) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| Water SCHEMBL8424505 | 0.81 | RAB9A (0.54) | RAB9AIDO1HTR2AALDH1A1MAPT | |
| SCHEMBL6141237 | 0.81 | ALDH1A1 (0.56) | RAB9AIDO1HTR2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | UBE INDUSTRIES, LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1500642-A1 | 3-SUBSTITUTED OXYGLUTARIC DIESTER COMPOUND, OPTICALLY ACTIVE 3-SUBSTITUTED OXYGLUTARIC MONOESTER COMPOUND, AND PROCESSES FOR PRODUCING THESE | Ube Industries, Ltd. (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | OGDH, GLUL, ADSL | RAB9A 3213/4885IDO1 1398/4885HTR2A 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.